William Furey, DO
Family Medicine · Voorhees, NJNPI 1790822427
Payments from drug & device makers
Across 346 payments — averaging $14.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$945
- AstraZeneca$751
- Amgen$598
- Amarin Pharma, Inc.$575
- Kowa Pharmaceuticals America, Inc.$328
- Novo Nordisk$212
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,839100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 72 | $945 |
| AstraZeneca | 36 | $751 |
| Amgen | 43 | $598 |
| Amarin Pharma, Inc. | 46 | $575 |
| Kowa Pharmaceuticals America, Inc. | 23 | $328 |
| Novo Nordisk | 19 | $212 |
| Astellas Pharma US Inc | 15 | $208 |
| Merck | 15 | $207 |
| AbbVie(2 entities) | 14 | $202 |
| Pfizer | 13 | $181 |
| Boehringer Ingelheim | 19 | $167 |
| Novartis | 9 | $138 |
| Lilly USA, LLC | 6 | $88 |
| Johnson & Johnson | 3 | $46 |
| Bayer | 2 | $40 |
| Exact Sciences | 2 | $34 |
| Kaleo, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$108
How this compares
$4,845 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 135 | $115,255 |
| FarxigaDapagliflozin Propanediol | 77 | $82,956 |
| JardianceEmpagliflozin | 56 | $72,161 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $55,427 |
| OzempicSemaglutide | 35 | $42,438 |
| JanuviaSitagliptin Phosphate | 20 | $30,254 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $17,209 |
| TradjentaLinagliptin | 12 | $16,924 |
| XareltoRivaroxaban | 13 | $15,070 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $14,374 |
| MyrbetriqMirabegron | 12 | $11,015 |
| Rosuvastatin Calcium | 645 | $10,647 |
| Valsartan | 245 | $9,647 |
| Icosapent Ethyl | 17 | $9,113 |
| VascepaIcosapent Ethyl | 15 | $8,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $181 | $115,255135 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $751 | $91,04688 claims |
| Boehringer IngelheimJardiance, Tradjenta | $167 | $89,08568 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $945 | $87,01095 claims |
| Novo NordiskOzempic | $212 | $42,43835 claims |
| MerckJanuvia | $207 | $30,25420 claims |
| Johnson & JohnsonXarelto | $46 | $15,07013 claims |
| Astellas Pharma US IncMyrbetriq | $208 | $11,01512 claims |
| AbbVieSynthroid | $202 | $1,40743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Voorhees
- Robert DavisVoorhees$17K
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.